Background and Purpose-Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors modulating metabolic and inflammatory responses of phagocytes to stimuli such as fatty acids and their metabolites. We studied the role of PPARs in macrophages exposed to low-density lipoprotein (LDL) modified by secretory phospholipase A 2 (PLA). Methods and Results-By analyzing PPAR ligand-binding domain luciferase reporter activation, we observed that PLA-LDL transactivates PPAR␣ and PPAR␦, but not PPAR␥. We confirmed that PLA-LDL induced PPAR response element reporter activation by endogenous PPAR␣ and PPAR␦ in human THP-1 macrophages. By using THP-1 cells with a stable knockdown of PPAR␣ and PPAR␦, we showed that PLA-LDL-activated PPAR␦ altered macrophage gene expression related to lipid metabolism and lipid droplet formation. Although PPAR␣/␦ silencing did not affect cholesterol and triglyceride accumulation in PLA-LDL-treated macrophages, PPAR␦ activation by PLA-LDL attenuated macrophage inflammatory gene expression induced by interferon ␥ and lipopolysaccharide. Conclusions-PPAR␦ activation by PLA-LDL does not influence lipid accumulation in PLA-LDL-treated macrophages. However, it attenuates macrophage inflammatory responses, thus contributing to an anti-inflammatory cell phenotype. (Arterioscler Thromb Vasc Biol. 2010;30:313-320.)
T he uptake of modified lipoproteins by macrophages, resulting in the formation of lipid-laden foam cells, is a key event during atherosclerotic lesion development. 1 Foam cell formation is usually associated with signs of inflammation, and inflammation accompanies atherosclerosis through all stages of lesion progression. 2 However, on uptake of lipoproteins, macrophages also exhibit homeostatic responses to lower lipid accumulation and to attenuate inflammation. The nuclear receptor family of peroxisome proliferator-activated receptors (PPARs), consisting of PPAR␣, PPAR␥, and PPAR␦, plays an important role in regulating lipid metabolism and inflammation in macrophages and other vascular cells. 3 The activation of PPARs was described for oxidized low-density lipoprotein (oxLDL), 4,5 oxidized phospholipids, 6 or very LDL (VLDL). 7 The lipolysis of lipoproteins (eg, by lipoprotein lipase [LPL] or endothelial lipase) may also generate potent PPAR ligands. [7] [8] [9] [10] A consequence of PPAR activation is enhanced cholesterol efflux from macrophages 5, 11 and reduced inflammation. 12 Initially, only PPAR␣ and PPAR␥ were ascribed a clear antiatherosclerotic effect, 13 whereas some ambiguity existed about the contribution of PPAR␦ to atherosclerosis development, given its positive involvement in macrophage lipid accumulation 14 and the antiatherosclerotic effects of PPAR␦ gene deletion. 15 However, recent studies 16, 17 clearly showed antiatherogenic effects of PPAR␦, especially under proinflammatory conditions. In addition, PPAR␥ and PPAR␦ activation favors a macrophage phenotype switch towards an alternatively activated M2 phenotype. 18 This macrophage phenotype switch is supposed to reduce inflammation and contribute to the beneficial effects of PPAR agonists to ameliorate insulin resistance and possibly atherosclerosis. 19 -22 LDL modified by secretory phospholipase A 2 (PLA-LDL) is readily taken up by macrophages, resulting in foam cell formation. 23, 24 These events underlie a well-described proatherogenic action of secretory phospholipases A 2 . 25, 26 The intracellular mechanisms accompanying PLA-LDL-induced foam cell formation are less understood. In monocytic cells, we noticed that PLA-LDL activated the cytoprotective phosphatidylinositol 3-kinase-Akt pathway, which was attributed to PLA-LDLassociated nonesterified fatty acids (NEFAs). 27 Here we report that PLA-LDL, via its associated NEFA, activates PPAR␣ and PPAR␦ in human macrophages. Although activation of PPARs by PLA-LDL does not alter lipid accumu-lation, PLA-LDL attenuates proinflammatory macrophage gene expression in a PPAR␦-dependent fashion.
Methods
For a description of oil red staining, intracellular cholesterol and triglyceride analysis, quantitative reverse transcription-polymerase chain reaction, and Western blotting, please refer to the supplemental information (available at http://atvb.ahajournals.org).
Cell Culture
THP-1 human acute monocytic leukemia cells and RAW264.7 mouse macrophages were cultured in RPMI medium 1640 supplemented with 10% heat-inactivated fetal calf serum, 2-mmol/L glutamine, 100-U/mL penicillin, and 100-g/mL streptomycin. Macrophage differentiation of THP-1 cells was induced by treatment with 100-nmol/L phorbol 12-myristate 13-acetate for 48 hours. Human monocytes were isolated from buffy coats (DRK-Blutspendedienst Baden-Württemberg-Hessen, Institut für Transfusionsmedizin und Immunhämatologie, Frankfurt, Germany) using Ficoll density centrifugation followed by magnetic separation with positive selection (CD14 MicroBeads; Miltenyi Biotec, Auburn, Calif). Monocytes were differentiated into macrophages by culture in macrophage serum-free medium (Invitrogen, Karlsruhe, Germany) containing 50-ng/mL human recombinant macrophage-colonystimulating factor (PeproTech, Rocky Hill, NJ) for 6 days.
LDL Isolation and Treatment
Human LDL (dϭ1.02-1.06 g/mL) was isolated from the plasma samples of healthy volunteers by sequential ultracentrifugation and maintained in the presence of 0.2-mmol/L EDTA to prevent oxidation. Modification of LDL by PLA, bovine serum albumin treatment, and oxidation were performed as previously described. 27 PLA-LDL preparations contained 0.5 to 1.2 moL of NEFA per milligram of LDL protein compared with 0.07 to 0.09 mol/mg in untreated LDL, as measured by an NEFA colometric detection kit (Wako Chemicals, Neuss, Germany). PLA treatment did not affect LDL cholesterol and triglyceride content.
Luciferase Reporter Assays
RAW264.7 or THP-1 cells were seeded at 2ϫ10 5 per well in a 12-well plate. The THP-1 cells were differentiated into macrophages before transfection. For PPAR transactivation assays, cells were transfected using a transfection reagent (JetPEI; PolyPlus Transfection, Illkirch, France) with 1.5 g of pFR-luc reporter plasmid, 0.15 g of Gal4-fusion receptor plasmids pFA-CMV-PPAR-ligandbinding domain (LBD) (both provided by Manfred Schubert-Zsilavecz, Goethe University Frankfurt) 28 and 0.01 g of pRL-CMV (Promega, Mannheim, Germany) to normalize for transfection efficiency. For PPAR response element (PPRE) reporter assays, cells were transfected with 1 g of p(AOX) 3 -TK-luc (provided by Christopher Glass, MD, PhD, University of California, San Diego) and 0.02 g of pRL-CMV. Six hours after transfection, the medium was changed and cells were treated with lipoproteins or PPAR agonists for 18 hours (transactivation assay) or 36 hours (PPRE reporter) before measuring luciferase activity.
PPAR␣ and PPAR␦ Knockdown
To create THP-1 cell lines with a stable knockdown of PPAR␣ and PPAR␦, cells were infected with lentiviruses coding for PPAR␣ and PPAR␦ shRNA or nontargeting control shRNA (MISSION shRNA; Sigma, Taufkirchen, Germany); and lentivirally transduced THP-1 clones were selected by culture in medium containing 1 g/mL of puromycin.
Statistical Analysis
Data are presented as meanϮSEM. Data were analyzed by a one-way analysis of variance test with a Bonferroni post hoc mean comparison using OriginPro 7.5 (OriginLab, Northhampton, Mass.). Differences were considered statistically significant at PϽ0.05.
Results
Lipolysis of lipoprotein particles may generate PPAR ligands. We investigated whether the treatment of LDL with PLA 2 (from Naja mossambica) results in PPAR transactivation. 28 For this purpose, we transfected RAW264.7 macrophages with plasmids encoding a Gal4 fusion receptor pFA-CMV-PPAR-LBD, containing the hinge region and LBD of PPAR␣, PPAR␥, or PPAR␦, together with a Gal4-driven luciferase reporter plasmid and stimulated cells with lipoproteins or synthetic PPAR ligands. Figure 1 shows that PPAR agonists, such as Wy14643, rosiglitazone, and GW0742, induced a PPAR transactivation. LDL did not activate PPARs, whereas PLA-LDL activated PPAR␣-LBD comparably to the effect of the Wy14643 synthetic ligand (Fig. 1A) . Activation of PPAR␦-LBD by PLA-LDL was approximately 50% of the effect achieved with the synthetic agonist GW0742 (Fig. 1B) . In contrast, PLA-LDL had a minimal effect on PPAR␥-LBD. However, as expected, PPAR␥-LBD was activated by oxLDL, a known PPAR␥ agonist (Fig. 1C ). 4 Thus, PLA-LDL can activate LBDs of PPAR␣ and PPAR␦, but not PPAR␥, likely by generating endogenous ligands.
To explore the effect of PLA-LDL on endogenous PPARs, we used THP-1 macrophages transfected with a plasmid containing the PPRE of acyl-coenzyme A oxidase. THP-1 cells contain all three PPARs and present a suitable model for studying the role of individual PPARs in lipid metabolism and foam cell formation. 14 As shown in Fig. 1D , PLA-LDL dose dependently activated the PPRE reporter to the extent comparable to the effects achieved with synthetic PPAR␣ (Wy14643) and PPAR␦ (GW0742) agonists. We also confirmed PPRE activation by LDL modified by more physiologically relevant group V secretory PLA (Supplemental Figure 1 ). In contrast, incubation of cells with PLA 2 alone had no effect on PPRE activity and treatment of LDL with PLA 2 in the presence of the calcium chelator EGTA to inhibit PLA 2 markedly suppressed PPRE activation (Supplemental Figure 2 ). LDL phospholipolysis generates NEFAs, and NEFAs and their oxidative metabolites are known PPAR activators. To investigate the role of NEFA in PPAR activation by PLA-LDL, we depleted PLA-LDL of fatty acids by incubation with an excess of fatty acid-free bovine serum albumin and reisolation of PLA-LDL. 27 As shown in Figure 1E , fatty acid depletion abrogated PPRE reporter activation in PLA-LDLtreated THP-1 macrophages. PLA-LDL was reported to induce foam cell formation in murine 23, 24 and human 29 macrophages. Confirming these data, we observed that incubation of THP-1 macrophages with PLA-LDL induced lipid accumulation, as assessed by oil red O staining ( Fig. 2A-C ). Control incubation with LDL caused no visible lipid droplet formation. Strikingly, analysis of total cholesterol and triglycerides in PLA-LDL-treated THP-1 macrophages revealed that the uptake of PLA-LDL resulted in only a moderate increase of cellular cholesterol, but caused an almost 10-fold increase in triglycerides ( Fig. 2D ). To assess the role of NEFAs in lipid accumulation induced by PLA-LDL, we analyzed the cholesterol and triglyceride content of THP-1 cells treated with PLA-LDL-depleted of fatty acids by bovine serum albumin treatment and reisolation ( Fig. 2E ).
Bovine serum albumin treatment reduced PLA-LDL NEFA content from 1.15Ϯ0.09 to 0.19Ϯ0.03 mol/mg and caused PLA-LDL aggregation, consistent with previous observations (data is meanϮSEM). 30 Cells incubated with NEFA-depleted PLA-LDL accumulated significantly more cholesterol compared with cells incubated with mock-treated PLA-LDL. However, the triglyceride content of cells treated with NEFAdepleted PLA-LDL was reduced. This indicates that NEFAs in PLA-LDL are at least in part responsible for triglyceride accumulation in PLA-LDL-treated macrophages.
Next, we questioned whether PPARs are involved in lipid accumulation induced by PLA-LDL treatment. To assess the role of PPAR␣ and PPAR␦ in PLA-LDL-induced changes of lipid metabolism, we created THP-1 lines with a stable knockdown of these nuclear receptors. The knockdown was verified by quantitative polymerase chain reaction in THP-1 cells after macrophage differentiation (Fig. 3A) . Differentiation did not influence PPAR␣ messenger RNA (mRNA) levels, whereas PPAR␦ mRNA expression increased (data not shown). PPAR␦ shRNA reduced PPAR␦ mRNA in macrophages by more than 80%, whereas for PPAR␣, shRNA lowered mRNA by approximately 60%. Western blot analysis in THP-1 macrophages showed that PPAR␣ and PPAR␦ protein levels were reduced to 45% and 35% of control, respectively, in corresponding knockdown cells (Fig. 3B) . To verify the functionality of the knockdown, we analyzed PPRE reporter activation by selective PPAR␣ and PPAR␦ ligands and PLA-LDL in THP-1 macrophages. As shown in Fig. 3C , the PPRE reporter response towards the specific agonists Wy14643 and GW0742 was significantly reduced in the corresponding knockdown lines. The reporter activity towards PLA-LDL was reduced by approximately 50% in THP-1 cells with either a PPAR␣ or PPAR␦ knockdown (Fig.  3D) . Thus, it appears that both PPAR␣ and PPAR␦ contribute to PLA-LDL-induced PPRE reporter activation.
Next, we analyzed PLA-LDL-induced changes in the expression of PPAR target genes associated with lipid metabolism in control and PPAR␣/PPAR␦ knockdown THP-1 macrophages. As shown in Fig. 4A , PLA-LDL induced the mRNA of lipid droplet-associated protein adipophilin in cells transduced with control shRNA. Carnitine palmitoyltransferase 1 (CPT-1), which is involved in fatty acid oxidation, was also induced by PLA-LDL. In contrast, mRNA expression of CD36, adipocyte triglyceride lipase, ATP-binding cassette transporter A1 (ABCA1), or apolipoprotein E was not induced in PLA-LDL-treated THP-1 macrophages (Supplemental Figure 3 ). We also observed induction of adipophilin and CPT-1 mRNA expression by PLA-LDL and the PPAR␦ agonist GW501516 in primary human macrophages (Fig.  4B) . The knockdown of PPAR␣ did not cause significant changes in the expression of adipophilin and CPT-1, neither in control nor in PLA-LDL-treated cells. Interestingly, in PPAR␦-silenced cells, the expression of adipophilin was elevated 10-fold. The expression of CPT-1 and CD36 was also elevated, probably reflecting ligand-independent basal repressor activity of PPAR␦. 31 The activating effect of PLA-LDL on the expression of adipophilin and CPT-1 was lost in PPAR␦ knockdown THP-1 macrophages. We then analyzed lipid accumulation in cells transduced with control or PPAR␣/PPAR␦ shRNA. As expected from the gene expression profile, lipid accumulation was not affected by silencing PPAR␣. Despite profound changes of gene expression, neither the cholesterol nor the triglyceride content of untreated or PLA-LDL-treated PPAR␦ knockdown cells differed from that of cells transduced with control lentivirus (Fig. 4C) . Oil red staining also revealed no differences in cells with PPAR␣/PPAR␦ being silenced (data not shown).
The activation of PPAR␦ has recently been shown to suppress inflammatory gene expression in the development of atherosclerotic lesions, resulting in delayed atherosclerosis progression. 16, 17 Thus, we questioned whether PLA-LDLinduced PPAR␦ activation may influence inflammatory gene expression in THP-1 macrophages. For this purpose, we analyzed macrophage responses towards interferon (IFN) ␥, a cytokine inducing classic M1 macrophage activation. 32 As shown in Fig. 5A , cells transduced with control shRNA responded to IFN␥ with increased expression of typical M1-associated genes, such as CXCL9 (MIG) and CXCL10 (IP-10), 33 and the proinflammatory chemokine MCP-1. Induction was significantly attenuated in the presence of PLA-LDL. In contrast, in THP-1 macrophages transduced with PPAR␦ shRNA, PLA-LDL no longer inhibited inflammatory gene induction by IFN␥. Cells transduced with PPAR␣ shRNA still responded to PLA-LDL with an attenuated inflammatory response to IFN␥, although for CXCL9, the inhibition did not reach statistical significance. We also tested whether PLA-LDL or the synthetic PPAR␦ agonist GW501516 influenced the inflammatory responses of primary human macrophages. Figure 5B shows that both PLA-LDL and GW501516 inhibited induction of TNF␣, IL-12p40, and IL-6 mRNAs in lipopolysaccharide-treated macrophages. These data indicate that PPAR␦ activation by PLA-LDL in part accounts for dampening inflammation.
Discussion
Macrophage foam cell formation is accompanied by counterregulatory mechanisms aimed at lowering lipid accumulation and terminating inflammation. We show that PPAR activation in cells exposed to proatherogenic PLA-LDL may contribute to these counterbalancing mechanisms. Although PPAR activation is not sufficient to prevent lipid accumulation in PLA-LDL-treated macrophages, PPAR␦ activation by PLA-LDL may dampen macrophage inflammatory responses and, thus, support an anti-inflammatory macrophage phenotype.
Previously, several modified lipoprotein species have been shown to affect signaling by PPARs. Activation of PPAR␥ by oxLDL is well characterized; this may activate cholesterol efflux through increased ABCA1 expression, 5 and it may attenuate inflammation. 34 -36 Lipolysis of lipoproteins by LPL or endothelial lipase also generates PPAR ligands, which reduce inflammation and provoke changes in lipid metabolism. [7] [8] [9] [10] 37 We show that another pathologically important type of LDL modification, such as phospholipolysis, causes activation of PPARs in human macrophages. In contrast to modifications by LPL or endothelial lipase, which predominantly take place at the surface of the endothelium, modification of LDL by PLA 2 also occurs within the vessel wall. This becomes relevant during inflammation, when enhanced secretory PLA 2 production by cells of the vascular wall occurs. Under these conditions, PPAR activation may be a critical regulator to balance excessive inflammation. Interestingly, previous studies showed no effect of PLA 2 treatment on PPAR␣-LBD activation by LDL or VLDL in endothelial cells, whereas LPL converted lipoproteins into potent PPAR␣ activators, although both treatments released similar fatty acid amounts. 8 Under our experimental settings, VLDL, and LDL treated by LPL, was able to activate PPRE reporter, although slightly less potently than PLA-LDL (data not shown). These discrepancies may reflect the differences in lipoprotein uptake and metabolism by endothelial cells and macrophages and differences between LBD and PPRE reporter systems. In murine macrophages, LPL treatment of VLDL activated PPAR␦. 7 Murine macrophages, in contrast to human macrophages, express little PPAR␣, potentially leading to species-specific responses towards lipolytically modified lipoproteins. 38 NEFAs and their oxidative metabolites are well-known PPAR ligands. We show that NEFAs generated by LDL phospholipolysis is critical for PPAR activation by PLA-LDL. However, it appears that in our system, using resting macrophages, NEFA oxidative modifications do not significantly contribute to PPAR activation. Along this line, the PPAR␥ LBD reporter was activated by oxLDL but not PLA-LDL. In addition, PPRE reporter activation by PLA-LDL was affected neither by inhibitors of cyclooxygenase nor lipoxygenase; activation was not affected by the lipophylic antioxidant butylated hydroxytoluene (data not shown). Whether activated macrophages, which show increased cyclooxygenase 2 expression, reveal a distinct pattern of PPAR responses towards PLA-LDL merits further investigation.
PPARs play important roles in the regulation of lipid metabolism, modulating the expression of genes involved in lipid transport, storage, or fatty acid oxidation. We show that PLA-LDL changes the expression of some genes involved in fatty acid oxidation, such as CPT-1 or adipophilin, involved in lipid droplet formation, both established PPAR␦ targets. Indeed, PPAR␦ silencing abolished the induction of these genes by PLA-LDL. However, the analysis of PPAR␦dependent changes in gene expression is complicated by enhanced expression of PPAR target genes as the result of PPAR␦ knockdown, because PPAR␦ in its unligated state represses distinct target genes. 31 Interestingly, we observed increased expression of several PPAR␥ targets, such as CD36, aP2, and ABCA1, in PPAR␦-silenced cells (Fig. 4 ), suggesting significant cross-talk of these nuclear receptors in macrophages. In contrast, we failed to observe PPAR␦- dependent regulation of adipocyte triglyceride lipase in human macrophages, whereas it was shown to be an important PPAR␦ target in murine macrophages, suggesting species specificity in regulating adipocyte triglyceride lipase expression. 37 PLA-LDL caused massive triglyceride accumulation in macrophages, which is similar to the effects of VLDL. 39 Triglyceride accumulation was dependent on PLA-LDL NE-FAs, similar to PPAR activation. We also noticed that NEFA depletion increased cholesterol accumulation in PLA-LDL- treated macrophages. This could be explained by increased aggregation of NEFA-depleted PLA-LDL, consistent with the findings of previous reports. 23, 30 In addition, triglyceride accumulation may promote lysosomal cholesterol efflux, thus preventing lysosomal cholesterol retention. 40 However, there seems to be no PPAR-dependent regulation of cholesterol or triglyceride metabolism under our experimental setting. Despite profound changes of gene expression in PPAR␦silenced cells, these cells showed an unaltered cholesterol and triglyceride content with or without PLA-LDL stimulation. Several considerations should be taken into account to explain these divergent results. Although adipophilin was shown to contribute to foam cell formation and atherosclerosis, it is rapidly degraded in the absence of lipid droplets. 41, 42 Therefore, changes in adipophilin mRNA expression may not reflect changes in its biological activity. Changes of fatty acid oxidation evoked by PPAR␦-dependent mechanisms may be too subtle to significantly affect fatty acid/triglyceride fluxes in macrophages.
Another important characteristic of PPARs is their ability to attenuate macrophage inflammatory responses, which likely contributes to delayed atherosclerosis progression in the presence of PPAR ligands. 13, 16, 17 Our data suggest that PLA-LDL attenuated IFN␥-and lipopolysaccharide-induced M1 macrophage polarization-associated gene expression in a PPAR␦-dependent fashion. Thus, PPAR␦ activation in PLA-LDL-induced foam cells may represent a desensitization mechanism aimed at counterbalancing excessive inflammation, similar to PPAR␥ activation in oxLDL-treated macrophages. 34 -36 Our data are in line with results obtained in murine macrophages, in which attenuated inflammatory responses likely contribute to delayed atherosclerosis development in apolipoprotein E-knockout mice treated with PPAR␦ agonists. 16 In contrast, PPAR␣ activation by PLA-LDL seems not to modulate inflammatory responses in our experimental model, although the anti-inflammatory effects of PPAR␣ activation are described. 38 This may reflect the specificity of PPAR␦ vs PPAR␣ anti-inflammatory actions towards IFN␥ stimulation and also distinct target genes suppressed by PPAR␣ or PPAR␦. Although we did not observe an altered expression of tissue factor or matrix metalloproteinase 9, two known targets of PPAR␣ in monocytes/macrophages, by PLA-LDL (data not shown), we can assume other targets be modulated by PPAR␣ under conditions of PLA-LDL stimulation in macrophages. In summary, our observations suggest that PPAR␦ activation in PLA-LDL-treated macrophages suppresses macrophage inflammatory responses without affecting lipid accumulation. It can be speculated that strategies to activate PPAR␦ should reduce plaque inflammation and, thus, help dampen atherosclerosis progression.
